STOCK TITAN

Insulet to Announce First Quarter 2023 Financial Results on May 4, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Insulet Corporation (NASDAQ: PODD) plans to release its Q1 2023 financial results on May 4, 2023, after market closure. A conference call will follow at 4:30 p.m. Eastern Time for management to discuss the results. Investors can access this via the Investor Relations section of the website or by phone. Insulet is recognized for its innovative Omnipod® tubeless insulin pump technology, aimed at improving treatment for diabetes. The Omnipod 5 Automated Insulin Delivery System represents a significant advancement, offering seamless integration with continuous glucose monitors.

Positive
  • Anticipated Q1 2023 earnings report may show growth in revenue.
  • Innovative technology such as Omnipod 5 could enhance market positioning.
Negative
  • None.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2023 on May 4, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod® 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible smartphone or Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2023 Insulet Corporation. Omnipod and Omnipod 5 are registered trademarks of Insulet Corporation.

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations (978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications (978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When will Insulet Corporation release its Q1 2023 earnings report?

Insulet Corporation will release its Q1 2023 earnings report on May 4, 2023.

What time is the conference call for Insulet's Q1 2023 earnings?

The conference call for Insulet's Q1 2023 earnings will be at 4:30 p.m. Eastern Time on May 4, 2023.

How can I access the Q1 2023 earnings call for Insulet?

You can access the Q1 2023 earnings call through the Investor Relations section of Insulet's website or by phone.

What is the significance of the Omnipod 5 system for Insulet Corporation?

The Omnipod 5 system is significant as it integrates with continuous glucose monitors, potentially improving diabetes management.

Insulet Corporation

NASDAQ:PODD

PODD Rankings

PODD Latest News

PODD Stock Data

18.00B
69.75M
0.34%
103.31%
4.29%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ACTON